Research Author

Mette Skalshøi Kjær

Novo Nordisk (Denmark)

ORCID OpenAlex profile

0Studies tracked

0Claims cite

0Videos use

Average study score: 81/100

Bibliography

Studies by this author

2 studies attributed to Mette Skalshøi Kjær on the platform. Click a card to read the full analysis.

Study

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

To investigate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo in adults with biopsy-confirmed NASH-related compensated cirrhosis.

Mod-High

Rohit Seth Loomba,Manal F. Abdelmalek,Matthew J. Armstrong+8 more

Read analysis

Study

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3.

High

Philip N. Newsome,Iris Kliers,Laura Østergaard+7 more

Read analysis